ValCare Medical

Minimally Invasive Treatment for Valve Disease

Health Tech & Life Sciences
Private

Company Overview

Snapshot

Founded in June 2012 by Samuel Shaolian, ValCare Medical operates with 11–50 employees. The company has raised $23 million across three funding rounds from four investors. In April 2024, ValCare Medical announced a corporate restructuring and appointed a new CEO.

Business overview

ValCare Medical develops innovative minimally-invasive technologies for treating mitral and tricuspid regurgitation. Its product portfolio includes solutions for mitral valve repair and replacement, as well as tricuspid valve repair. The company's core technology features a D-shaped ring that functions as both a mitral annulus repair tool and a docking station for its proprietary replacement prosthesis, serving the cardiology and medical device markets globally.

Strategic signal

In May 2024, ValCare Medical announced the enrollment of the first two patients in its AMEND™ TS EU Pilot Study. This milestone is a critical validation of the company's transseptal mitral valve repair technology, signaling progress toward clinical adoption and potential market expansion for its minimally invasive solutions in Europe.

Company Intelligence Q&A

What was a significant recent operational change at ValCare Medical?
In April 2024, ValCare Medical announced a corporate restructuring and appointed a new CEO, indicating a strategic shift in leadership and organizational direction.
What is the status of ValCare Medical's AMEND™ TS EU Pilot Study?
In May 2024, ValCare Medical announced the enrollment of the first two patients in its AMEND™ TS EU Pilot Study, marking a key step in the clinical development of its transseptal mitral valve repair technology.
When did ValCare Medical form its Scientific Advisory Board?
In July 2024, ValCare Medical announced the formation of its Scientific Advisory Board, comprising renowned mitral valve experts to guide its clinical and product development strategies.
When did ValCare Medical achieve its first-in-human transseptal implant for mitral valve repair?
In January 2021, ValCare Medical announced the first-in-human transseptal implant of its AMEND™ Annuloplasty Ring for mitral valve repair.
Which investor participated in ValCare Medical's funding round in September 2018?
In September 2018, Accelmed participated in a funding round for ValCare Medical.

External links